SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Baron R 2003 Anatomy and Biology of Bone Matrix and Cellular Elements, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. American Society for Bone and Mineral Research, Washington, DC, USA.
  • 2
    Hattner R, Epker BN, Frost HM 1965 Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature 206: 489490.
  • 3
    Takahashi H, Epker B, Frost HM 1964 Resorption precedes formative activity. Surg Forum 15: 437438.
  • 4
    Sarnsethsiri P, Hitt OK, Eyring EJ, Frost HM 1971 Tetracycline-based study of bone dynamics in pycnodysostosis. Clin Orthop 74: 301312.
  • 5
    Parfitt AM 1982 The coupling of bone formation to bone resorption: A critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res 4: 16.
  • 6
    Martin TJ 1993 Hormones in the coupling of bone resorption and formation. Osteoporos Int 3(Suppl 1): 121125.
  • 7
    Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N 2003 Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144: 54415449.
  • 8
    Teitelbaum SL, Ross FP 2003 Genetic regulation of osteoclast development and function. Nat Rev Genet 4: 638649.
  • 9
    Goltzman D 2002 Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov 1: 784796.
  • 10
    Tolar J, Teitelbaum SL, Orchard PJ 2004 Osteopetrosis. N Engl J Med 351: 28392849.
  • 11
    Rodan GA 1991 Mechanical loading, estrogen deficiency, and the coupling of bone formation to bone resorption. J Bone Miner Res 6: 527530.
  • 12
    Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 15: 15261536.
  • 13
    Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C 1999 Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84: 23632368.
  • 14
    Ravn P, Clemmesen B, Christiansen C 1999 Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24: 237244.
  • 15
    Ravn P, Thompson DE, Ross PD, Christiansen C 2003 Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 33: 150158.
  • 16
    Burr DB, Robling AG, Turner CH 2002 Effects of biomechanical stress on bones in animals. Bone 30: 781786.
  • 17
    Burr DB 2002 Targeted and nontargeted remodeling. Bone 30: 24.
  • 18
    Burr DB, Turner CH 2003 Biomechanics of Bone. American Society for Bone and Mineral Research, Washington, DC, USA.
  • 19
    Li J, Sato M, Jerome C, Turner CH, Fan Z, Burr DB 2005 Microdamage accumulation in the monkey vertebra does not occur when bone turnover is suppressed by 50% or less with estrogen or raloxifene. J Bone Miner Metab 23(Suppl): 4854.
  • 20
    Mashiba T, Mori S, Burr DB, Komatsubara S, Cao Y, Manabe T, Norimatsu H 2005 The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 23(Suppl): 3642.
  • 21
    Li J, Mashiba T, Burr DB 2001 Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 69: 281286.
  • 22
    Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB 2001 Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28: 524531.
  • 23
    Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15: 613620.
  • 24
    Martin TJ, Sims NA 2005 Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11: 7681.
  • 25
    Thompson ER, Baylink DJ, Wergedal JE 1975 Increases in number and size of osteoclasts in response to calcium or phosphorus deficiency in the rat. Endocrinology 97: 283289.
  • 26
    Mundy GR, Bonewald LF 1990 Role of TGF beta in bone remodeling. Ann N Y Acad Sci 593: 9197.
  • 27
    Centrella M, McCarthy TL, Canalis E 1991 Transforming growth factor-beta and remodeling of bone. J Bone Joint Surg Am 73: 14181428.
  • 28
    Hayden JM, Mohan S, Baylink DJ 1995 The insulin-like growth factor system and the coupling of formation to resorption. Bone 17: 93S98S.
  • 29
    Baylink DJ, Finkelman RD, Mohan S 1993 Growth factors to stimulate bone formation. J Bone Miner Res 8(Suppl 2): S565S572.
  • 30
    Howard GA, Bottemiller BL, Turner RT, Rader JI, Baylink DJ 1981 Parathyroid hormone stimulates bone formation and resorption in organ culture: Evidence for a coupling mechanism. Proc Natl Acad Sci USA 78: 32043208.
  • 31
    Taranta A, Migliaccio S, Recchia I, Caniglia M, Luciani M, De Rossi G, Dionisi-Vici C, Pinto RM, Francalanci P, Boldrini R, Lanino E, Dini G, Morreale G, Ralston SH, Villa A, Vezzoni P, Del Principe D, Cassiani F, Palumbo G, Teti A 2003 Genotype-phenotype relationship in human ATP6i-dependent autosomal recessive osteopetrosis. Am J Pathol 162: 5768.
  • 32
    Henriksen K, Gram J, Schaller S, Dahl BH, Dziegiel MH, Bollerslev J, Karsdal MA 2004 Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II (ADOII). Am J Pathol 164: 15371545.
  • 33
    Bollerslev J, Steiniche T, Melsen F, Mosekilde L 1989 Structural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: A study of two radiological types. Bone 10: 1924.
  • 34
    Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Vaananen HK, Halleen JM 2004 Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 50: 883890.
  • 35
    Del Fattore A, Peruzzi B, Rucci N, Recchia I, Cappariello A, Longo M, Fortunati D, Ballanti P, Iacobini M, Luciani M, Devito R, Pinto R, Caniglia M, Lanino E, Messina C, Cesaro S, Letizia C, Bianchini G, Fryssira H, Grabowski P, Shaw N, Bishop N, Hughes D, Kapur R, Datta H, Taranta A, Fornari R, Migliaccio S, Teti A 2005 Clinical, genetic and cellular analysis of forty-nine osteopetrotic patients: Implications for diagnosis and treatment. J Med Genet 43: 315325.
  • 36
    Bollerslev J, Marks SC Jr, Pockwinse S, Kassem M, Brixen K, Steiniche T, Mosekilde L 1993 Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone 14: 865869.
  • 37
    Karsdal MA, Henriksen K, Sorensen MG, Gram J, Schaller S, Dziegiel MH, Heegaard AM, Christophersen P, Martin TJ, Christiansen C, Bollerslev J 2005 Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166: 467476.
  • 38
    Fratzl-Zelman N, Valenta A, Roschger P, Nader A, Gelb BD, Fratzl P, Klaushofer K 2004 Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis. J Clin Endocrinol Metab 89: 15381547.
  • 39
    Nishi Y, Atley L, Eyre DE, Edelson JG, Superti-Furga A, Yasuda T, Desnick RJ, Gelb BD 1999 Determination of bone markers in pycnodysostosis: Effects of cathepsin K deficiency on bone matrix degradation. J Bone Miner Res 14: 19021908.
  • 40
    Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, Bernardini S, Faraggiana T, Yoneda T, Mundy GR, Boyce BF, Baron R, Teti A 2000 Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 151: 311320.
  • 41
    Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ 2001 Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104: 205215.
  • 42
    Soriano P, Montgomery C, Geske R, Bradley A 1991 Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64: 693702.
  • 43
    Horne WC, Neff L, Chatterjee D, Lomri A, Levy JB, Baron R 1992 Osteoclasts express high levels of pp60c-src in association with intracellular membranes. J Cell Biol 119: 10031013.
  • 44
    Li YP, Chen W, Liang Y, Li E, Stashenko P 1999 Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet 23: 447451.
  • 45
    Visentin L, Dodds RA, Valente M, Misiano P, Bradbeer JN, Oneta S, Liang X, Gowen M, Farina C 2000 A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J Clin Invest 106: 309318.
  • 46
    Rzeszutek K, Sarraf F, Davies JE 2003 Proton pump inhibitors control osteoclastic resorption of calcium phosphate implants and stimulate increased local reparative bone growth. J Craniofac Surg 14: 301307.
  • 47
    Schaller S, Henriksen K, Sveigaard C, Heegaard AM, Helix N, Stahlhut M, Ovejero MC, Johansen JV, Solberg H, Andersen TL, Hougaard D, Berryman M, Shiodt CB, Sorensen BH, Lichtenberg J, Christophersen P, Foged NT, Delaisse JM, Engsig MT, Karsdal MA 2004 The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 19: 11441153.
  • 48
    Dai XM, Zong XH, Akhter MP, Stanley ER 2004 Osteoclast deficiency results in disorganized matrix, reduced mineralization, and abnormal osteoblast behavior in developing bone. J Bone Miner Res 19: 14411451.
  • 49
    Sakagami N, Amizuka N, Li M, Takeuchi K, Hoshino M, Nakamura M, Nozawa-Inoue K, Udagawa N, Maeda T 2005 Reduced osteoblastic population and defective mineralization in osteopetrotic (op/op) mice. Micron 36: 688695.
  • 50
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ 2006 Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821831.
  • 51
    Dobbins DE, Sood R, Hashiramoto A, Hansen CT, Wilder RL, Remmers EF 2002 Mutation of macrophage colony stimulating factor (Csf1) causes osteopetrosis in the tl rat. Biochem Biophys Res Commun 294: 11141120.
  • 52
    Lian JB, Marks SC Jr 1990 Osteopetrosis in the rat: Coexistence of reductions in osteocalcin and bone resorption. Endocrinology 126: 955962.
  • 53
    Tuukkanen J, Koivukangas A, Jamsa T, Sundquist K, MacKay CA, Marks SC Jr 2000 Mineral density and bone strength are dissociated in long bones of rat osteopetrotic mutations. J Bone Miner Res 15: 19051911.
  • 54
    Demiralp B, Chen HL, Koh AJ, Keller ET, McCauley LK 2002 Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. Endocrinology 143: 40384047.
  • 55
    Burr DB 2005 Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size. Curr Osteoporos Rep 3: 1924.
  • 56
    Koh AJ, Demiralp B, Neiva KG, Hooten J, Nohutcu RM, Shim H, Datta NS, Taichman RS, McCauley LK 2005 Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146: 45844596.
  • 57
    Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teitelbaum SL 2006 Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116: 21522160.
  • 58
    Everts V, Delaisse JM, Korper W, Jansen DC, Tigchelaar-Gutter W, Saftig P, Beertsen W 2002 The bone lining cell: Its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 17: 7790.
  • 59
    Jones SJ, Gray C, Boyde A 1994 Simulation of bone resorption-repair coupling in vitro. Anat Embryol (Berl) 190: 339349.
  • 60
    Schwartz Z, Lohmann CH, Wieland M, Cochran DL, Dean DD, Textor M, Bonewald LF, Boyan BD 2000 Osteoblast proliferation and differentiation on dentin slices are modulated by pretreatment of the surface with tetracycline or osteoclasts. J Periodontol 71: 586597.
  • 61
    Sheu TJ, Schwarz EM, Martinez DA, O'Keefe RJ, Rosier RN, Zuscik MJ, Puzas JE 2003 A phage display technique identifies a novel regulator of cell differentiation. J Biol Chem 278: 438443.
  • 62
    Sheu TJ, Schwarz EM, O'Keefe RJ, Rosier RN, Puzas JE 2002 Use of a phage display technique to identify potential osteoblast binding sites within osteoclast lacunae. J Bone Miner Res 17: 915922.
  • 63
    Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, Bertoncello I, Drake F, Zavarselk S, Tellis I, Hertzog P, Debouck C, Kola I 1999 Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14: 16541663.
  • 64
    Lark MW, Stroup GB, James IE, Dodds RA, Hwang SM, Blake SM, Lechowska BA, Hoffman SJ, Smith BR, Kapadia R, Liang X, Erhard K, Ru Y, Dong X, Marquis RW, Veber D, Gowen M 2002 A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone 30: 746753.
  • 65
    Kumar S, Rehm S, Boyce B, Birmingham J, Stroup GB, Jerome C, Weir P 2005 Treatment of young male monkeys for 12 months with a highly potent inhibitor of cathepsin K inhibits bone resorption and increases bone mineral density and strength. J Bone Miner Res 20S1; F232.
  • 66
    Adams CS, Shapiro IM 2003 Mechanisms by which extracellular matrix components induce osteoblast apoptosis. Connect Tissue Res 44(Suppl 1): 230239.
  • 67
    Li CY, Jepsen KJ, Majeska RJ, Zhang J, Ni R, Gelb BD, Schaffler MB 2006 Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J Bone Miner Res 21: 865875.
  • 68
    Hayden JM, Mohan S, Baylink DJ 1995 The insulin-like growth factor system and the coupling of formation to resorption. Bone 17: 93S98S.
  • 69
    Baylink DJ, Finkelman RD, Mohan S 1993 Growth factors to stimulate bone formation. J Bone Miner Res 8:S2; S565S572.
  • 70
    Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G 1999 Stimulation of bone formation in vitro and in rodents by statins. Science 286: 19461949.
  • 71
    Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, Ernst M, Martin TJ 2004 Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest 113: 379389.
  • 72
    Weitzmann MN, Roggia C, Toraldo G, Weitzmann L, Pacifici R 2002 Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 110: 16431650.
  • 73
    Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP 2002 High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346: 15131521.
  • 74
    Lazowski DA, Fraher LJ, Hodsman A, Steer B, Modrowski D, Han VK 1994 Regional variation of insulin-like growth factor-I gene expression in mature rat bone and cartilage. Bone 15: 563576.
  • 75
    Robinson JA, Riggs BL, Spelsberg TC, Oursler MJ 1996 Osteoclasts and transforming growth factor-beta: Estrogen-mediated isoform-specific regulation of production. Endocrinology 137: 615621.
  • 76
    Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL 2002 Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 277: 4400544012.
  • 77
    Bikle DD, Sakata T, Leary C, Elalieh H, Ginzinger D, Rosen CJ, Beamer W, Majumdar S, Halloran BP 2002 Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res 17: 15701578.
  • 78
    Henriksen K, Neutzsky-Wulff AV, Christiansen C, Martin TJ, Karsdal MA 2006 Osteoclasts secrete non-bone derived signals that induce bone nodule formation. J Bone Miner Res 21:S1; M198.
  • 79
    Henriksen K, Nielsen RH, Neutzsky-Wulff AV, Christiansen C, Martin TJ, Karsdal MA 2006 Osteoclast number but not activity may be the determinant factor for sustained osteoclast effect on bone formation. J Bone Miner Res 21:S1; SA418.
  • 80
    Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K 2006 Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4: 111121.
  • 81
    Mundy GR, Elefteriou F 2006 Boning up on ephrin signaling. Cell 126: 441443.
  • 82
    Iki M, Akiba T, Matsumoto T, Nishino H, Kagamimori S, Kagawa Y, Yoneshima H 2004 Reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study. Osteoporos Int 15: 981991.
  • 83
    Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM 2004 A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19: 10591066.
  • 84
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB 1998 Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial. J Bone Miner Res 13: 14311438.
  • 85
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349: 12071215.
  • 86
    Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349: 12161226.